Leadership & Pay ·
Anna Eramo, M.D., resigned as Chief Medical Officer on June 8, 2026, effective June 15, 2026, for personal reasons
LBRXLB Pharmaceuticals Inc
Anna Eramo, M.D., resigned as Chief Medical Officer on June 8, 2026, effective June 15, 2026, for personal reasons. She will serve as a full-time consultant through September 15, 2026. Under a separation agreement, if she completes the consulting period, she will receive her base salary monthly until June 15, 2027, a prorated 2026 target annual bonus, and the acceleration of 66,143 unvested stock options on September 15, 2026. The company will also reimburse COBRA healthcare premiums for up to 12 months. The company stated the departure is unrelated to clinical operations and does not expect a material impact on clinical development activities. LB Pharmaceuticals Inc is a biopharmaceutical company focused on the development of clinical-stage product candidates.